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Abstract: The development of melanogenic inhibitors is important for the prevention of 
hyperpigmentation, and, recently, consideration has been given to natural materials or 
traditionally used ingredients such as Chinese medicine. The aim of this study is the 
evaluation of a new anti-melanogenic candidate, kadsuralignan F, from the natural plant 
Kadsura coccinea, as well as the determination of mechanisms of melanogenesis inhibition 
at a molecular level. Kadsuralignan F significantly reduced melanin synthesis in a   
dose-dependent manner in a murine melanocyte cell line and human skin equivalents. 
There was no direct inhibition on mushroom tyrosinase or cell-extract tyrosinase activity, 
and mRNA expression of tyrosinase and other melanogenic genes such as tyrosinase-related 
protein-1 (trp-1) or trp-2 were not affected by kadsuralignan F. Interestingly, the protein 
level of tyrosinase was dramatically downregulated with kadsuralignan F treatment. We 
found that a decrease of tyrosinase protein by kadsuralignan F was fully recovered by 
MG132, a proteasome inhibitor, but not by chloroquine, a lysosome inhibitor. In this study, 
we found that kadsuralignan F, a lignan from an extract of Kadsura coccinea, has an inhibitory 
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activity on melanin synthesis through tyrosinase degradation. These findings suggest that 
kadsuralignan F can be used as an active ingredient for hyperpigmentation treatment. 
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1. Introduction 
Melanin synthesis and distribution contributes to mammalian skin color [1]. Melanin pigments have 
a role in the protection of skin from ultraviolet irradiation, as well as various oxidative stresses [2]. 
However, irregular synthesis of melanin may cause problems with the skin, and there are a number  
of hyperpigmentary disorders or conditions attributed to this, such as melasma, solar lentigo,   
post-inflammatory hyperpigmentation, or freckles [3]. Thus, effective skin whitening ingredients could 
be useful for clinical therapy, as well as for cosmetic applications. 
Melanin is synthesized in the melanosome, a unique organelle in melanocytes [4]. There are three 
types of melanogenic enzymes in the melanosome: tyrosinase, tyrosinase-related protein (TRP)-1 and 
TRP-2. It is well known that tyrosinase, a type I membrane glycoprotein, plays the most critical role in 
melanin synthesis [5]. Tyrosinase participates in the critical rate-limiting step in melanin synthesis. 
Tyrosinase catalyzes the two initial steps in melanogenesis, the hydroxylation of tyrosine to 
dihydroxyphenylalanine (DOPA) and the oxidation of DOPA to DOPA-quinone [6]. Tyrosinase is 
synthesized in the endoplasmic reticulum (ER), and is processed by post-translational modifications, 
including N-glycosylation in the Golgi apparatus [7]. After maturation in the Golgi, tyrosinase moves 
through the trans-Golgi network to melanosomes for melanin synthesis, or to the degradation 
machinery as a regulatory process for balance between synthesis and degradation of the protein [8]. 
Tyrosinase is degraded by two pathways; the proteolysis ER associated protein degradation (ERAD) in 
the ubiquitin proteasome system (UPS) [9], or the endosomal/lysosomal degradation system [10]. 
Because of the key regulatory role of tyrosinase on melanogenesis, many previous studies have focused 
on tyrosinase inhibitors, especially those occurring from natural sources. The stimulation of tyrosinase 
degradation has been become a new target in discovering skin-whitening agents [8,11]. Substances such as 
phenylthiourea [10], phospholipase D2 [12], inulavosin [13], terrein [14], and dimethoxytolyl 
propylresorcinol [15] can induce tyrosinase degradation, resulting in reduced melanin synthesis. 
Kadsura coccinea (Lem.) A. C. Smith (Schizandraceae) is widely distributed throughout southwest 
mainland China. The dried roots of K. coccinea, called Hei Lao Hu in Chinese, are used as a traditional 
medicine for the treatment of gastric and duodenal ulcers, chronic gastritis, acute gastroenteritis, and 
rheumatoid arthritis [16]. Previous phytochemical and biological investigations of K. coccinea have 
yielded some lignans and triterpenoids, and have identified their anti-tumor [17], nitric oxide   
inhibitory [18], and anti-HIV actions [19], as well as their protection of the liver [20]. Recently, Shu et al. 
reported the isolation of new lignans from the air-dried roots of K. coccinea, and elucidation of the 
structures and physicochemical properties [21]. Among them, a dibenzocyclooctadiene lignan showed 
high inhibition activity on melanin synthesis, and the IR and NMR spectra analysis revealed that the 
compound was identified as kadsuralignan F. In this study, we report the anti-pigmentation property of Int. J. Mol. Sci. 2013, 14  1657 
 
kadsuralignan F on melanogenesis, due to tyrosinase degradation. To our knowledge, it is the first 
molecular mechanism study on the anti-melanogenesis effects of kadsuralignan F. 
2. Results and Discussion 
Lignans are one of the main groups of phytoestrogens [22]. It is well known that phytoestrogens 
have physiological effects, such as estrogen-receptor binding and anti-oxidant activity effects [23,24]. 
Previous reports have shown various effects of lignans on skin: macelignan inhibited PAR-2 
melanosome transfer in keratinocytes [25]; licarin E regulated MMP-1; and procollagen I was 
expressed in fibroblasts [26]. Kadsuralignans were isolated from K. coccinea, and their biological effects 
were reported, such as nitric oxide inhibition [18] and protection on t-butyl hydroperoxide-induced 
primary rat hepatocyte injury [27]. In this study, we first identify the anti-melanogenic effect, followed 
by the molecular mechanism of kadsuralignan F (Figure 1), a kadsuralignan. 
Figure 1. Chemical structure of kadsuralignan F. 
 
Figure 2. Effects of kadsuralignan F on the proliferation of melan-A cells. The cells were 
cultured with the indicated concentrations of kadsuralignan F for 3 days. Results are 
expressed as a percentage of the control (DMSO), and values are the average ± SE 
(standard error) of three determinations. ** p < 0.01 vs. DMSO. 
 
We used murine a melanocyte cell line melan-A cells to study melanogenesis inhibition by 
kadsuralignan F. Melan-A cells were cultured for three days at the indicated concentrations of 
kadsuralignan F, and cell viability was assessed by WST-1 assay (Figure 2). No significant change of 
cell viability was found in cells which were treated with up to 11.87 μM (5 ppm) kadsuralignan F, 
when compared with control cells (98% at 2.37 μM (1 ppm) and 94% at 11.87 μM, respectively). Int. J. Mol. Sci. 2013, 14  1658 
 
Therefore, further experiments in this study were conducted using concentrations less than 11.87 μM 
kadsuralignan F. 
Quantification of melanin content indicated that kadsuralignan F significantly reduced the melanin 
synthesis in a dose-dependent manner (56% at 2.97 μM, 53% at 5.94 μM, and 33% at 11.87 μM) 
(Figure 3A). As shown in Figure 3B, the color of representative cell pellets clearly showed inhibitory 
activity of kadsuralignan F on melanogenesis, which became brighter with increasing concentration. 
Figure 3. Effect of kadsuralignan F on melanin synthesis in melan-A cells. The melanin 
content of the cells was measured after 7 days of treatment with indicated concentrations of 
kadsuralignan F. (A) The melanin content was measured. Results are expressed as a 
percentage of the control (DMSO), and values are the average ± SE of three 
determinations. ** p < 0.01 vs. DMSO. (B) Photographs of melan-A cell pellet lysates. 
Cells were cultured with kadsuralignan F in 75 cm
2 cell culture flasks for three days, were 
detached using trypsin-EDTA, and subsequently collected by centrifuge. Cell pellets were 
then dissolved in 2N NaOH containing 10% DMSO. 
 
The skin-whitening ability of kadsuralignan F was also tested in human skin equivalents. After nine 
days of treatment, pigmentation of kadsuralignan F-treated skin equivalents was compared against 
controls which were treated with the same volume of DPBS. Kadsuralignan F treatment at 47.48 µM 
and 94.96 µM (20 ppm and 40 ppm, respectively), which showed no cytotoxicity on skin equivalents, 
increased the brightness of the tissues relative to the control (Figure 4). Human skin equivalents, such 
as MelanoDerm, can implement many biological reactions that appear in physiological human skin, 
including interactions between melanocytes and keratinocytes, and skin pigmentation. Therefore,  
in vitro biosystems such as these are widely applied in many studies to evaluate the whitening 
efficacies of cosmetic and pharmaceutical agents. The result demonstrated that kadsuralignan F would 
be more effective for skin whitening than kojic acid, a proven whitening agent used in the test as a 
positive control [28], as the ΔL* value of the skin equivalents treated with 47.48 µM of kadsuralignan 
F was equal to that treated with 1% kojic acid (70.37 mM).  
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Figure 4. The effect of kadsuralignan F on human skin equivalents. Dark (from   
African-American skin, n = 2) MelanoDerms were treated with kadsuralignan F and kojic 
acid for nine days. Images were taken and the ΔL* value was calculated by comparing the 
increased L* values of each skin equivalent against a control.  
 
Figure 5. Effect of kadsuralignan F on tyrosinase activity in vitro. The inhibition effect on 
tyrosinase activity was evaluated using (A) mushroom tyrosinase and (B) melan-A cell 
extract by spectrophotometric methods. (A) Various concentrations of kadsuralignan F (■) 
and kojic acid (◊) were incubated with mushroom tyrosinase and tyrosine. (B) Various 
concentrations of kadsuralignan F (■) and kojic acid (◊) were incubated with melan-A cell 
extract and L-DOPA. Results are expressed as a percentage of the control, and values are 
the average ± SE of three determinations. 
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Since tyrosinase is the key regulatory enzyme for melanin production [5], the ability of 
kadsuralignan F on tyrosinase activity inhibition was investigated with mushroom tyrosinase and 
DOPA oxidase activity of mammalian tyrosinase. Tyrosinases from mushroom and melan-A cell 
extract were treated with different concentrations of either kadsuralignan F or kojic acid, and were 
incubated in the presence of substrates. In this cell-free assay system, we could try higher 
concentrations of kadsuralignan F compared to the cellular melanin assay, as it is more suitable for 
testing the direct inhibition of tyrosinase activity. As shown in Figure 5, kadsuralignan F had no 
significant inhibitory effect on tyrosine hydroxylase activity (Figure 5A) or DOPA oxidase activity 
(Figure 5B). Kojic acid, a well known tyrosinase inhibitor, suppressed both tyrosinase activities   
dose-dependently. 
As there was no direct inhibition on tyrosinase activity by kadsuralignan F, further investigation of 
the expression of melanogenic proteins was performed. To investigate whether kadsuralignan F 
inhibits gene expression of melanogenic proteins, real-time reverse transcription polymerase chain 
reaction (qRT-PCR) assays were conducted in melan-A after 24 h treatment of kadsuralignan F. 
mRNA transcription levels of tyrosinase, trp-1, and trp-2 mRNA were not affected by kadsuralignan F 
(Figure 6B). Mitf, a master transcriptional regulator of melanogenic proteins was decreased to   
72% levels of the untreated control at the highest concentration of kadsuralignan F applied.   
We also examined shorter time (2 and 6 h) treatment of kadsuralignan F, there was no significant 
change in those melanogenic genes expression (data not shown). Western blot analysis revealed that 
kadsuralignan F remarkably decreased the protein expression of tyrosinase (Figure 6A). The 
expression levels of TRP-1, TRP-2, and MITF were also diminished, but the decreases were not 
significant. Although it has been observed that the reduction in levels of Mitf gene expression was very 
low. Therefore, the amount of the MITF protein changes were expected to be low impact, and it was 
confirmed as a result of the Western blot experiment. These results suggest that melanin synthesis 
inhibition by kadsuralignan F did not result from the decrease of gene expression of melanogenic 
proteins, but was affected by the decrease in the expression level of tyrosinase protein, which might be 
related to post-translational modification processes of tyrosinase in melanocytes. 
Tyrosinase is endogenously removed by the ubiquitin-mediated proteasomal degradation system [8]. 
Recent studies have reported that agents degraded tyrosinase via activation of the UPS resulting in the 
acceleration of tyrosinase degradation [9,29]. To investigate whether tyrosinase degradation by 
kadsuralignan F is involved in proteasomal or lysosomal pathway, analysis using proteolysis inhibitors 
was conducted. Tyrosinase degradation is mediated via proteasome, and this degradation could affect 
melanin synthesis in melanocytes [30]. For an evaluation of kadsuralignan F on post-translational 
tyrosinase degradation, we introduced MG-132, a proteasome inhibitor, and/or chloroquine, a 
lysosomal proteolysis inhibitor. After 24 h of serum starvation, melan-A cells were treated with 
cycloheximide to inhibit protein synthesis, and then the proteolysis inhibitors were added for 1 h 
followed by 6 h of kadsuralignan F treatment. It was found that the tyrosinase decrease due to 
kadsuralignan F treatment was recovered by pretreatment with MG-132. However, chloroquine 
treatment did not show any effect on the tyrosinase recovery (Figure 7). These results indicate that 
proteasomal tyrosinase degradation was mediated by kadsuralignan F treatment. Further study is 
needed to investigate the relationship between kadsuralignan F treatment and the ubiquitination   
of tyrosinase. Int. J. Mol. Sci. 2013, 14  1661 
 
Figure 6. Effect of kadsuralignan F on melanogenesis-related gene expression of protein 
level and mRNA level in melan-A cells. (A) The cells were treated with the indicated 
concentrations of kadsuralignan F for three days, and Western blotting of tyrosinase,   
TRP-1, TRP-2, and MITF was performed. The loading control was assessed using   
anti-GAPDH antibody. The band intensities of melanogenic proteins were normalized by 
the band intensities of GAPDH as an internal control for each condition, and values are the 
average ± SE of three determinations. * p < 0.05 vs. DMSO; (B) The cells were cultured 
with kadsuralignan F for 24 h. mRNA levels were analyzed by real-time quantitative PCR. 
Gapdh was used as an internal standard, and melanogenesis-related gene mRNA/gapdh 
mRNA ratios are expressed relative to the control (DMSO), where values are the   
average ± SE of three determinations. * p < 0.05 vs. DMSO. 
  
Figure 7. Effect of kadsuralignan F on tyrosinase degradation in melan-A cells. The cells 
were pretreated with cycloheximide, following treatment of proteolysis inhibitors (MG-132 
and/or chloroquine), and they were then incubated with 11.87 μM kadsuralignan F. After 
treatment, Western blot analysis was conducted to analyze tyrosinase levels using   
whole cell lysates with anti-tyrosinase antibody. β-Actin was used as internal control for 
each condition. 
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3. Experimental Section  
3.1. Reagents 
Kojic acid, 3,4-dihydroxyphenilalanine (L-DOPA), tyrosine, mushroom tyrosinase, arbutin, 
cycloheximide, MG-132 and chloroquine were purchased from Sigma Chemical Co. (St. Louis, MO, 
USA). Protease inhibitor cocktail (CompleteTM) was from Roche Applied Science (Mannheim, 
Germany). Kadsuralignan F was isolated from K. coccinea and was purified by column 
chromatography, preparative TLC, and reverse-phase HPLC [21]. Briefly, dried K. coccinea (30 kg) 
was refluxed in 95% ethanol three times. All extracts were merged and then concentrated under 
vacuum to obtain a sticky solid (2.6 kg). The solid was suspended in water, and was then repeatedly 
extracted with petroleum ether, methylene chloride, ethyl acetate, and butanol. A residue extracted 
with methylene chloride (240 g) was separated by silica gel chromatography (gradient elution with 
benzene-acetic ether from 0:100 to 100:0) and was followed by HPLC. 12 fractions were gained from 
the extract, and the third fraction was concentrated and applied to silica gel chromatography and 
HPLC. Among them, kadsuralignan F (30.4 mg) was isolated. The structure of kadsuralignan F was 
elucidated by means of its physicochemical properties as determined through spectroscopic analyses. 
3.2. Cell Culture 
Melan-A cells were cultured in RPMI 1640 (Lonza ltd., Basel, Switzerland), supplemented with 
10% heat-inactivated fetal bovine serum (Lonza ltd., Basel, Switzerland), 100 U/mL potassium 
penicillin and 100 mg/mL streptomycin sulfate (Lonza ltd., Basel, Switzerland), and phorbol   
12-myristate 13-acetate (Sigma-Aldrich, St Louis, MO, USA). Cells were maintained with 10% CO2 in 
a humidified chamber (Thermoscientifics, Waltham, MA, USA) at 37 °C. 
3.3. Measurement of Cell Viability 
Cell viability was determined by using cell proliferation reagent WST-1 (Roche Applied Science, 
Mannheim, Germany) following the manufacturer’s Instructions. Briefly, 10 µL of WST-1 solution 
was added to each well containing melan-A cells which were cultured with kadsuralignan F for 72 h. 
After 4 h of incubation at 37 °C under 10% CO2, absorbance was measured using a SpectraMax 190 
microplate reader (Molecular Devices Corp., Sunnyvale, CA, USA) at 450/690 nm. The percentage 
cytotoxicity was calculated by comparing data from treated cells with that of the control. 
3.4. Determination of Melanin Contents 
Melan-A cells were seeded into 48-well plate at 1.5 × 10
4 cells/well. After 24 h of incubation, cells 
were treated with various concentrations of kadsuralignan F for 6 days. Every 3 days, media were 
removed and replaced with fresh media containing the samples. After treatment, the cells were washed 
with Dulbecco’s phosphate buffer saline (DPBS) and were dissolved in 2 N NaOH containing 10% 
DMSO for 1 h at 60 °C. Absorbance was measured at 475 nm, and melanin content was determined 
against a standard curve of synthetic melanin (Sigma-Aldrich, St. Louis, MO, USA). The values were 
normalized by the total protein contents in each sample. Int. J. Mol. Sci. 2013, 14  1663 
 
3.5. Whitening Assessment in Human Skin Equivalents 
Dark (from African-American skin) Human epidermal equivalents (MelanoDerm) were purchased 
from MatTek Corp. (Ashland, MA, USA). MelanoDerms were grown at the air–liquid interface, and 
the maintenance medium was replenished every 2 days. Kadsuralignan F was treated at 47.48 µM and 
94.96 µM prepared in DPBS, which showed no cytotoxicity on skin equivalents. DPBS and kojic acid 
(1%) treatments were used for vehicle-treated and positive controls, respectively. Pigmentation of the 
skin equivalents was assessed by comparing the change in L* value, a value of CIE 1976 (L*, a*, b*) 
color space representing the brightness, as previously reported [31]. The level of pigmentation was 
monitored by calculating the difference (ΔL* value) between the mean L* values at day 9 and at day 0 
for each skin equivalent. 
3.6. Identification of Tyrosinase Inhibition Activities 
For the mushroom tyrosinase assay, 0.1 M potassium phosphate buffer (pH 6.8) containing samples, 
mushroom tyrosinase (10 units), and tyrosine (0.55 mM) were incubated together at 37 °C for 10 min 
in a 96-well plate. After incubation, absorbance was measured by the microplate reader at a wavelength 
of 475 nm for tyrosine hydroxylation to DOPA. For cellular tyrosinase assay, total melan-A cell lysate 
was extracted by incubation in lysis buffer (0.1 M phosphate buffer, pH 6.8, 1% Triton X-100) at 4 °C 
for 1 h. The lysate was then centrifuged at 15,000× g for 30 min, and supernatant was collected. 
Cellular tyrosinase activity was assessed by reacting the mixture containing supernatant (40 µg), and 
L-DOPA (5.1 mM) with samples. During incubation at 37 °C for 30 min, absorbance was monitored at 
a wavelength of 475 nm in order to detect the conversion of DOPA to DOPA chrome via DOPA quinine. 
3.7. Western Blot Analysis 
Melan-A cells were cultured with samples for 72 h. Following harvesting and washing with DPBS, 
cells were either lysed in extraction buffer (0.1 M Tris-HCl, pH 7.2; 1% TritonX-100, 200 mM NaCl, 
protease inhibitor cocktail) at 4 °C. Each cell lysate (10 μg) was loaded onto 4~12% Bis-Tris sodium 
dodecyl sulfate/polyacrylamide gels for electrophoresis and was then transferred to nitrocellulose membranes 
(Invitrogen, Carlsbad, CA, USA). Membranes were blocked with 5% skim milk in Tris-buffered saline 
(TBS) containing 0.01% Tween-20 for 2 h at room temperature, before overnight incubation with 
primary antibody at 4 °C. The rabbit anti-tyrosinase, TRP-1 and TRP-2 antisera (αPEP7, αPEP1, and 
αPEP8, respectively) were a kind gift from Dr. V. J. Hearing (National Institutes of Health, Bethesda) 
and anti-microphthalmia-associated transcription factor (MITF) was purchased from Thermo Fisher 
Scientific (San Jose, CA, USA). After incubation, membranes were rinsed three times with TBS and 
were incubated with HRP-conjugated secondary antibodies (Santa Cruz, CA, USA) for 1 h at room 
temperature. After washing, membranes were subjected to Western Blotting Luminol Reagent (Santa 
Cruz, CA, USA) and were visualized using the LAS-3000 imaging system (Fuji Film, Tokyo, Japan). 
3.8. RNA Isolation and Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Melan-A cells cultured with samples for 24 h were washed twice with DPBS, and were lysed using 
Trizol (Invitrogen, Carlsbad, CA, USA) by vortexing and samples incubated for 10 min at room Int. J. Mol. Sci. 2013, 14  1664 
 
temperature followed by chloroform addition and centrifugation (12,000 rpm, 15 min, 4 °C). After 
centrifugation, the aqueous phase of the samples was collected and isopropanol was added. The 
mixture was incubated for 10 min at room temperature before centrifugation (12,000 rpm, 10 min,  
4 °C). RNA pellets were washed with 75% ethanol and cleaned up using RNeasy mini kit (Qiagen, 
Inc., Valencia, CA, USA) according to the manufacturer’s instructions. RNA yield was estimated by 
determining the optical density at 260 nm. Subsequently, cDNA was synthesized from total RNA (4 μg) 
with reverse transcriptase (Superscript Reverse Transcriptase (RT) II kit, Invitrogen, Carlsbad, CA, 
USA) at 50 °C for 1 h, following a denaturing step at 95 °C for 5 min according to the manufacturer’s 
instructions. The cDNA was amplified in a reaction mixture containing TaqMan universal PCR master 
mix (Applied Biosystems, Foster city, CA, USA) and probes for TaqMan gene expression assay 
(Applied Biosystems, Foster city, CA, USA) by 7300 Real Time PCR System (Applied Biosystems, 
Foster city, CA, USA). Real-time quantitative PCR analysis was carried out under the following 
conditions: 40 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 30 s, and a final extension 
at 72 °C for 60 s. Relative levels of each melanogenic protein mRNA was expressed compared to gapdh 
mRNA. The probes used were Mm00495817_m1 for tyrosinase, Mm00453201_m1 for tyrosinase 
related protein-1, Mm01225584_m1 for tyrosinase related protein-2, Mm00434954_m1 for mitf, and 
Mm99999915_g1 for gapdh. 
3.9. Statistical Analysis 
Statistical significance of all experimental data was determined by one-way ANOVA/Dunnett’s 
multiple comparison test, using MINITAB software program (14.0 for windows). Values of p < 0.05 
were considered to be statistically significant. 
4. Conclusions  
In this study, we first reported that kadsuralignan F, a new dibenzocyclooctadiene lignan from a 
traditional medicine K. coccinea, showed whitening activity, as identified by the mechanism of 
kadsuralignan F on melanogenesis inhibition.  We found that kadsuralignan F induced tyrosinase 
degradation via the proteasomal pathway, and subsequent melanin contents were reduced in melan-A 
cells and human skin equivalents. Overproduction and accumulation of melanin is related to 
hyperpigmentary skin disorders, and kadsuralignan F is an effective inhibitor of melanogenesis which 
can be useful as an effective skin-whitening agent. 
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